Earlier Diagnosis + Earlier Intervention = Better Outcomes
NeuroPointDX scientists have developed a blood panel that identifies differences in the way some children process certain proteins. These differences, or metabolic imbalances, are consistent with the diagnosis of autism spectrum disorder (ASD) as determined by the standard behavioral assessment. Our autism research study used the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition).
The blood panel we developed will be widely available soon. Stay tuned on this site and follow NeuroPointDX on social media for more information!
NeuroPointDX has discovered differences in molecules in the blood called metabolites of children with ASD that may allow earlier diagnosis of children across the spectrum. NeuroPointDX has validated a number of metabolic subtypes, or metabotypes, in an extensive study and will bring its test to market soon.
RESEARCH
For our autism research study, Children’s Autism Metabolome Project (CAMP), we enrolled over 1,100 children, 18-48 months old. The study was conducted at eight clinical sites across the country.
CAMP included children with ASD and other developmental delays, as well as typically-developing children. Based on our work in CAMP, we have developed the NeuroPointDX ASD Panel, a tool that can lead to an earlier autism diagnosis.
Posters & Publications
NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.
NeuroPointDX, through its parent company Stemina Biomarker Discovery, has published papers in peer-reviewed journals and presented research at meetings around the world.
